Patents by Inventor Ikuo Kushida

Ikuo Kushida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051322
    Abstract: Crystals of compounds represented by formula (I) having potential as drug substances for pharmaceuticals, as well as salts of compounds represented by formula (I) and their crystals.
    Type: Application
    Filed: January 12, 2023
    Publication date: February 13, 2025
    Inventors: Ikuo Kushida, Yoko Ito, So Yasui, Takashi Fukuyama, Nobuaki Sato, Taro Asaba
  • Publication number: 20240294491
    Abstract: This salt of the compound represented by formula (I) and crystals thereof are applicable as an active pharmaceutical ingredient of pharmaceutical products.
    Type: Application
    Filed: July 19, 2022
    Publication date: September 5, 2024
    Inventors: Ikuo KUSHIDA, Fusae KOMURA, Nao SHIBUGUCHI
  • Patent number: 11691990
    Abstract: The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34?5,39?5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: July 4, 2023
    Assignee: Eisai R&D Management Co., LTD
    Inventors: Jun Niijima, Hirofumi Kuroda, So Yasui, Yoko Ito, Ikuo Kushida
  • Patent number: 11420980
    Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: August 23, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kenshi Yoshida, Yoshiaki Ohashi, Tamaki Hoshikawa, Nobuaki Sato, Ikuo Kushida
  • Publication number: 20210323972
    Abstract: The present invention provides a crystal of the compound represented by formula (I) having applicability as a drug substance of pharmaceuticals.
    Type: Application
    Filed: May 7, 2018
    Publication date: October 21, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Ikuo Kushida, Yoko Ito, Masaaki Matsuda
  • Publication number: 20210198282
    Abstract: The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38, 40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34?5,39?5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Application
    Filed: August 14, 2019
    Publication date: July 1, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Jun NIIJIMA, Hirofumi KURODA, So YASUI, Yoko ITO, Ikuo KUSHIDA
  • Publication number: 20210024541
    Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Kenshi Yoshida, Yoshiaki Ohashi, Tamaki Hoshikawa, Nobuaki Sato, Ikuo Kushida
  • Patent number: 10259817
    Abstract: The present invention provides a crystal of (6S,9aS)-N-benzyl-8-({6-[3-4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: April 16, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ikuo Kushida, Yoko Ito
  • Patent number: 10221183
    Abstract: The present invention provides a crystal of (6S,9aS)-N-benzyl-8-({6-[3-4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 5, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ikuo Kushida, Yoko Ito
  • Publication number: 20180141950
    Abstract: The present invention provides a crystal of (6S,9aS)-N-benzyl-8-({6-[3-4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl} methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Application
    Filed: June 21, 2016
    Publication date: May 24, 2018
    Inventors: Ikuo Kushida, Yoko Ito
  • Patent number: 9550732
    Abstract: An organic carboxylic acid salt of 2-[(3S,4R)-1-{[2-chloro-6-(trifluoromethyl)phenyl]methyl}-3-{[1-(cyclohex-1-en-1-ylmethyl) piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]acetic acid and a crystal thereof.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: January 24, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kenshi Yoshida, Ikuo Kushida
  • Publication number: 20160318938
    Abstract: Provided are a crystal of a hydrate of compound 1, showing diffraction peaks at diffraction angles (2?±0.2°) of 10.7°, 10.9°, 14.4°, 19.1° and 22.8°, in powder X-ray diffraction, a crystal of compound 1 or hydrate thereof, showing diffraction peaks at diffraction angles (2?±0.2°) of 7.2°, 8.9°, 13.2°, 16.4° and 22.4°, in powder X-ray diffraction, a crystal of an anhydride of compound 1, showing diffraction peaks at diffraction angles (2?±0.2°) of 10.3°, 14.2°, 14.6°, 16.1° and 22.1°, in powder X-ray diffraction, and a crystal of compound 1 or hydrate thereof, showing diffraction peaks at diffraction angles (2?±0.2°) of 7.3°, 10.7°, 16.3°, 19.8° and 23.8°, in powder X-ray diffraction.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 3, 2016
    Applicant: PRISM PHARMA CO., LTD.
    Inventors: Ikuo KUSHIDA, Yukiko SUGAYA, Takenao ODAGAMI, Hiroyuki KOUJI
  • Publication number: 20160318957
    Abstract: Provided is a crystal of hydrate of 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, showing a diffraction peak at a diffraction angle (2?±0.2°) of 15.9°, in powder X-ray diffraction.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 3, 2016
    Applicant: PRISM PHARMA CO., LTD.
    Inventors: Ikuo KUSHIDA, Yukiko SUGAYA, Takenao ODAGAMI, Hiroyuki KOUJI
  • Publication number: 20160002165
    Abstract: An organic carboxylic acid salt of 2-[(3S,4R)-1-{[2-chloro-6-(trifluoromethyl)phenyl]methyl}-3-{[1-(cyclohex-1-en-1-ylmethyl) piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]acetic acid and a crystal thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 7, 2016
    Inventors: Kenshi Yoshida, Ikuo Kushida
  • Patent number: 8703954
    Abstract: The present invention provides a crystal of a 1.5 D-tartrate of a compound represented by the formula (1) having an A production inhibitory effect, characterized in that the crystal has a diffraction peak at a diffraction angle (20.2) of 23.2 in powder X-ray diffractometry; a crystal of a disulfate of the compound of the formula (1), characterized in that the crystal has a diffraction peak at a diffraction angle (20.2) of 17.1 in powder X-ray diffractometry; various other salts of the compound of the formula (1); crystal polymorphs of these salts; and the like, which are expected to be used as drug substances.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 22, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takuma Minamisono, Noritaka Kitazawa, Ikuo Kushida
  • Publication number: 20110275822
    Abstract: The present invention provides a crystal of a 1.5 D-tartrate of a compound represented by the formula (1) having an A production inhibitory effect, characterized in that the crystal has a diffraction peak at a diffraction angle (20.2) of 23.2 in powder X-ray diffractometry; a crystal of a disulfate of the compound of the formula (1), characterized in that the crystal has a diffraction peak at a diffraction angle (20.2) of 17.1 in powder X-ray diffractometry; various other salts of the compound of the formula (1); crystal polymorphs of these salts; and the like, which are expected to be used as drug substances.
    Type: Application
    Filed: February 24, 2010
    Publication date: November 10, 2011
    Inventors: Takuma Minamisono, Noritaka Kitazawa, Ikuo Kushida
  • Patent number: 7923563
    Abstract: An amorphous object of (3E)-1-[l(s)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the formula (1) and has A?-production inhibitory activity. The amorphous object has such satisfactory properties that it has excellent solubility, is stable, does not readily become a crystalline form, and has low hygroscopicity. It is hence suitable for use in pharmaceutical preparations.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: April 12, 2011
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ikuo Kushida, Eriko Doi, Koichi Ito
  • Publication number: 20100317860
    Abstract: Disclosed are crystals of the compound represented by Formula (1), which has A?-production-reducing effects and is a prodrug of compounds effective in treating neural degenerative diseases of which A? is the cause, for example, diseases such as Alzheimer's disease, Down syndrome, etc., and salts thereof or crystals of salts thereof. These are particularly useful as stock for pharmaceutical products.
    Type: Application
    Filed: January 26, 2009
    Publication date: December 16, 2010
    Inventors: Ikuo Kushida, Nobuaki Sato, Yoshiaki Sato
  • Patent number: 7737141
    Abstract: The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: June 15, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Teiji Kimura, Koki Kawano, Noritaka Kitazawa, Nobuaki Sato, Toshihiko Kaneko, Koichi Ito, Mamoru Takaishi, Ikuo Kushida
  • Patent number: 7655800
    Abstract: The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E6070.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: February 2, 2010
    Assignee: Eisai R & D Management Co., Ltd.
    Inventors: Charles E. Chase, Ikuo Kushida